Aviragen Therapeutics Inc Stock Nasdaq
Stocks
US0537611024
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 111M 97.92M 92.59M 83.98M 158M 10.69B 159M 1.11B 428M 5.45B 418M 409M 17.52B | P/E 2026 * |
-2.86x | P/E 2027 * | -0.54x |
|---|---|---|---|---|---|
| Enterprise Value | 111M 97.92M 92.59M 83.98M 158M 10.69B 159M 1.11B 428M 5.45B 418M 409M 17.52B | EV / Sales 2026 * |
0.94x | EV / Sales 2027 * | 47.4x |
| Free-Float |
98.52% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| 1 day | -8.47% |
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 2024-03-17 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-02-29 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 2025-05-18 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 2021-04-20 |
William Watson
BRD | Director/Board Member | 76 | 2022-08-03 |
Elaine Heron
BRD | Director/Board Member | 79 | 2021-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.47% | +1,187.88% | - | - | 111M | |
| -0.37% | -3.67% | +57.21% | +87.75% | 72.26B | |
| -0.07% | -2.70% | +37.74% | +86.90% | 60.24B | |
| -0.66% | +0.76% | +33.96% | +16.21% | 27.73B | |
| -0.14% | -2.75% | -14.13% | +356.79% | 25.73B | |
| +0.57% | +1.10% | +1.02% | -2.89% | 24.75B | |
| +1.10% | +1.86% | +25.07% | -7.59% | 20.74B | |
| -1.70% | +0.43% | +150.24% | +323.16% | 15.06B | |
| +0.36% | +2.01% | +49.51% | +160.70% | 14.41B | |
| +4.61% | -2.86% | -3.91% | +521.67% | 14.23B | |
| Average | -0.48% | -0.11% | +37.41% | +171.41% | 30.57B | |
| Weighted average by Cap. | +0.10% | -1.08% | +37.98% | +129.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 119M 104M 98.64M 89.46M 168M 11.38B 169M 1.18B 456M 5.81B 445M 436M 18.67B | 2.35M 2.07M 1.95M 1.77M 3.33M 226M 3.35M 23.4M 9.04M 115M 8.82M 8.63M 370M |
| Net income | -47.2M -41.51M -39.25M -35.6M -66.87M -4.53B -67.26M -470M -182M -2.31B -177M -173M -7.43B | -222M -195M -184M -167M -314M -21.27B -316M -2.21B -852M -10.85B -832M -814M -34.88B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
